Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years

Be the sponsor of this project!

What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis?  The major goal of this project is to test the hypothesis that IL4Rα blockade will prevent new soft tissue sarcoma engraftment, metastases and relapse by interfering with tumor cell – muscle stem cell interactions and thus represent an effective therapeutic strategy for children with rhabdomyosarcoma and other soft tissue sarcomas.  These studies in mice with humanized IL4Rα receptor and humanized IL-4 cytokine will serve as proof-of-concept for this novel immunotherapy for an often incurable form of sarcoma.